(Sharecast News) - Avacta said on Thursday it had agreed the design of a pivotal US trial for its lead cancer therapy with the US Food and Drug Administration, while reporting further clinical data that it said strengthened the case for its preCISION oncology platform.
The AIM-traded clinical-stage biotechnology company said...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE